LT2000082A - Aii antagonisto sulėtinto atpalaidavimo preparatas, jo gavimas ir panaudojimas - Google Patents

Aii antagonisto sulėtinto atpalaidavimo preparatas, jo gavimas ir panaudojimas

Info

Publication number
LT2000082A
LT2000082A LT2000082A LT2000082A LT2000082A LT 2000082 A LT2000082 A LT 2000082A LT 2000082 A LT2000082 A LT 2000082A LT 2000082 A LT2000082 A LT 2000082A LT 2000082 A LT2000082 A LT 2000082A
Authority
LT
Lithuania
Prior art keywords
sustained
release preparation
production
aii antagonist
angiotensin
Prior art date
Application number
LT2000082A
Other languages
English (en)
Other versions
LT4800B (lt
Inventor
Yasutaka Igari
Akira Saikawa
Yoshiyuki Inada
Shigeru Kamei
Original Assignee
Takeda Chemical Industries,Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries,Ltd filed Critical Takeda Chemical Industries,Ltd
Publication of LT2000082A publication Critical patent/LT2000082A/lt
Publication of LT4800B publication Critical patent/LT4800B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LT2000082A 1998-03-04 2000-08-31 Aii antagonisto sulėtinto atpalaidavimo preparatas, jo gavimas ir panaudojimas LT4800B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5236698 1998-03-04

Publications (2)

Publication Number Publication Date
LT2000082A true LT2000082A (lt) 2001-03-26
LT4800B LT4800B (lt) 2001-06-25

Family

ID=12912818

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2000082A LT4800B (lt) 1998-03-04 2000-08-31 Aii antagonisto sulėtinto atpalaidavimo preparatas, jo gavimas ir panaudojimas

Country Status (21)

Country Link
US (2) US6589547B1 (lt)
EP (1) EP1058541B1 (lt)
KR (1) KR20010086245A (lt)
CN (1) CN1291888A (lt)
AT (1) ATE258430T1 (lt)
AU (1) AU2745199A (lt)
BR (1) BR9908474A (lt)
CA (1) CA2318446C (lt)
DE (1) DE69914460T2 (lt)
EE (1) EE200000499A (lt)
ES (1) ES2214013T3 (lt)
HU (1) HUP0101439A3 (lt)
ID (1) ID25640A (lt)
IL (1) IL137979A0 (lt)
LT (1) LT4800B (lt)
LV (1) LV12585B (lt)
NO (1) NO20004350L (lt)
PL (1) PL342684A1 (lt)
SK (1) SK11902000A3 (lt)
WO (1) WO1999044590A1 (lt)
ZA (1) ZA991706B (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044590A1 (en) * 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
CA2371554C (en) 1999-04-28 2009-06-09 Shizue Nakagawa Pharmaceutical composition comprising an angiotensin ii antagonist for preventing, treating or development-inhibiting simple retinopathy and preproliferative retinopathy
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
AU3408801A (en) * 2000-02-18 2001-08-27 Takeda Chemical Industries Ltd Tnf-alpha inhibitors
AU2001232348A1 (en) * 2000-02-21 2001-08-27 Takeda Chemical Industries Ltd. Sustained release preparations of physiologically active compound hardly solublein water and production process and use of the same
US20030187038A1 (en) * 2000-08-25 2003-10-02 Yoshimi Imura Fibrinogen-lowering agents
AU2002210925A1 (en) * 2000-10-25 2002-05-06 Takeda Chemical Industries Ltd. Preventives/remedies for portal hypertension
US20040121008A1 (en) * 2001-03-16 2004-06-24 Keiko Shiraishi Process for producing sustained release preparation
EP1413315A4 (en) * 2001-08-03 2006-08-16 Takeda Pharmaceutical DRUGS WITH CONTINUOUS RELEASE
BRPI0105509B8 (pt) * 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
EP1444988A4 (en) * 2001-11-13 2007-04-25 Takeda Pharmaceutical CANCER AGENT
CA2468827A1 (en) * 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
AU2003292775A1 (en) * 2002-12-27 2004-07-29 Takeda Pharmaceutical Company Limited Body weight gain inhibitor
US20050038093A1 (en) * 2003-05-02 2005-02-17 Boehringer Ingelheim International Gmbh Treating diabetic retinopathy with angiotensin II receptor blockers
US7815894B2 (en) * 2003-05-29 2010-10-19 Jay W. Pettegrew Compounds, compositions and methods for medical imaging of neuropsychiatric disorders
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
EP1799203A1 (en) * 2004-10-07 2007-06-27 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of metabolic syndrome
EP1806137A4 (en) * 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
CA2598410A1 (fr) * 2005-02-21 2006-08-24 Flamel Technologies Forme pharmaceutique orale de losartan
AR055755A1 (es) * 2005-03-30 2007-09-05 Takeda Pharmaceutical Derivado de bencimidazol, procesos de obtencion, composiciones farmaceuticas y usos.
DE602006008962D1 (de) * 2005-08-22 2010-07-08 Alembic Ltd Verfahren zur herstellung von valsartan
CN102813635A (zh) * 2006-08-10 2012-12-12 武田药品工业株式会社 药物组合物
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
MY148370A (en) 2006-12-18 2013-04-15 Takeda Pharmaceutical Sustained-release composition and method for producing the same
CN101011393B (zh) * 2007-02-16 2010-10-06 广州柏赛罗药业有限公司 厄贝沙坦胃内滞留型缓释药物组合物
TWI415634B (zh) * 2007-03-28 2013-11-21 Takeda Pharmaceutical 固態醫藥組成物
KR101209319B1 (ko) * 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
AU2010251194B2 (en) 2009-05-20 2016-02-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical oral telmisartan solution
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2751907A (en) * 1953-09-18 1956-06-26 Bishop & Co Platinum Works J Pellet injector
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
JPS5671074A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IE802177L (en) 1980-10-21 1981-05-12 Takeda Chemical Industries Ltd Imidazol-5-ylacetic acid derivatives
JPS58157768A (ja) 1982-03-16 1983-09-19 Takeda Chem Ind Ltd ４−クロロ−２−フエニルイミダゾ−ル−５−酢酸誘導体
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4820843A (en) 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
CA1338238C (en) 1988-01-07 1996-04-09 David John Carini Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
US5015651A (en) 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
IE64514B1 (en) 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
ATE107517T1 (de) * 1989-05-25 1994-07-15 Takeda Chemical Industries Ltd Transdermales therapeutisches mittel.
EP0403158A3 (en) 1989-06-14 1991-12-18 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
KR0163595B1 (ko) 1989-06-30 1998-12-01 미리암디, 메코너헤이 치환된 이미다졸
CA2020073A1 (en) 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
EP0407342A3 (en) 1989-07-06 1991-07-10 Ciba-Geigy Ag Pyrimidine derivatives
EP0409332A3 (en) 1989-07-19 1991-08-07 Merck & Co. Inc. Substituted triazoles as angiotensin ii antagonists
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
ATE113281T1 (de) 1989-08-02 1994-11-15 Takeda Chemical Industries Ltd Pyrazol-derivate, verfahren zu deren herstellung und anwendung.
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
EP0434038A1 (en) 1989-12-22 1991-06-26 Takeda Chemical Industries, Ltd. Fused imidazole derivatives, their production and use
DE69129998T2 (de) 1990-02-15 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Pyrimidindionderivate, deren Herstellung und Verwendung
CA2036618C (en) * 1990-02-22 2002-10-29 Akira Morimoto Fused thiophene derivatives, their production and use
IL99246A0 (en) * 1990-09-10 1992-07-15 Abbott Lab Angiotensin ii receptor antagonists and pharmaceutical compositions containing them
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
TW274551B (lt) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
CZ36394A3 (en) * 1991-08-19 1994-07-13 Du Pont Substituted imidazilonone derivatives and pharmaceutical preparations based thereon
TW284688B (lt) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
GB2272899A (en) * 1992-11-30 1994-06-01 Du Pont Merck Pharma Angiotensin-11 receptor blocking cycloalkylbenzylimidazoles
EP0603712B1 (en) 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclic compounds having angiotensin II antagonistic activity and use thereof
US5288720A (en) * 1993-04-23 1994-02-22 American Cyanamid Company Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
JPH0789849A (ja) 1993-09-20 1995-04-04 Fujisawa Pharmaceut Co Ltd 徐放性製剤
DE69632684T2 (de) * 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
UA49880C2 (uk) 1996-03-29 2002-10-15 Смітклайн Бічам Корпорейшн Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) * 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
US6306826B1 (en) * 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
WO1999044590A1 (en) * 1998-03-04 1999-09-10 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof

Also Published As

Publication number Publication date
KR20010086245A (ko) 2001-09-10
US6589547B1 (en) 2003-07-08
CA2318446C (en) 2008-09-23
DE69914460D1 (de) 2004-03-04
EP1058541B1 (en) 2004-01-28
HUP0101439A2 (hu) 2001-10-28
LV12585A (en) 2000-12-20
AU2745199A (en) 1999-09-20
LV12585B (en) 2001-03-20
ZA991706B (en) 2000-10-03
HUP0101439A3 (en) 2002-09-30
ID25640A (id) 2000-10-19
WO1999044590A1 (en) 1999-09-10
PL342684A1 (en) 2001-07-02
NO20004350D0 (no) 2000-09-01
US7294344B2 (en) 2007-11-13
LT4800B (lt) 2001-06-25
ES2214013T3 (es) 2004-09-01
US20030198676A1 (en) 2003-10-23
BR9908474A (pt) 2000-12-05
CA2318446A1 (en) 1999-09-10
EE200000499A (et) 2002-02-15
EP1058541A1 (en) 2000-12-13
CN1291888A (zh) 2001-04-18
DE69914460T2 (de) 2004-10-28
NO20004350L (no) 2000-10-03
IL137979A0 (en) 2001-10-31
ATE258430T1 (de) 2004-02-15
SK11902000A3 (sk) 2001-02-12

Similar Documents

Publication Publication Date Title
ZA991706B (en) Sustained-release preparation for Aii Antagonist, production and use thereof.
CA2356310A1 (en) External preparations containing a basic drug
BR0014651A (pt) Inibidores de adesão de célula mediada por "alfa" l beta2
BG66115B1 (bg) Използване на рамиприл или негова фармацевтично приемлива сол за предотвратяване на конгестивна сърдечна недостатъчност
NO950297D0 (no) Prolinamidderivater
DE60140222D1 (de) "2-Oxo-1-Pyrrolidinderivate und ihre pharmazeutische Verwendung"
BG66085B1 (bg) Фенилаланинови производни
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DE69840645D1 (en) Benzamidinderivate
EP1350511A4 (en) MEDICAL COMPOSITIONS CONTAINING ASPIRIN
WO1999026932A8 (en) By amidino group substituted heterocyclic derivatives and their use as anticoagulants
BR9804027A (pt) Novos beta-ceto ésteres
MXPA04004805A (es) Peptido novedoso que tiene un efecto inhibidor de la enzima convertidora de angiotensina.
MXPA02002452A (es) Agentes preventivos y terapeuticos para enfermedades de oftalmicas.
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon
EA200100089A1 (ru) Предотвращение рецидива мигрени
DE60028928D1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
BR9812982A (pt) Agente anti-reumático
HU9202990D0 (en) A new application of quisqualate receptor antagonists
WO1998031704A3 (en) Tachykinin antagonists
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
FR2740337B1 (fr) Compositions pharmaceutiques stabilisees contenant un derive ayant une activite adrenergique
AU2003292775A1 (en) Body weight gain inhibitor
NO20014889L (no) Fremgangsmåte for fremstilling av medisinske midler

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20030303